Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.
The personalized vaccine was associated with a 45% lower risk of death in a real-world study.
Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.
Genetically modified natural killer cells led to remission in eight out of eleven patients with lymphoma or leukemia.
Edited T cells survive and thrive in three patients in the first U.S. trial using this approach.
“If you have the opportunity to be part of something that helps others, why wouldn’t you at least try it?”
The reference meeting for scientists, clinicians, regulators, drug developers, and patient advocates.
Immunotherapy may prolong survival compared with standard chemotherapy.
New research suggests how to better predict which patients will respond to immunotherapy.
The biological mechanisms responsible for the abscopal effect are still being investigated, but the immune system may play an big role.
Tecentriq plus Avastin improved both overall survival and patient-reported outcomes.
With new molecular “handles” and stimulating signals, metallic thin films become a stronghold for cancer-killing immune cells.
Researchers are working to understand why tumors may be resistant to T-cell immunotherapy, and to identify novel targets for immunotherapy.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
Study suggests immune-based cancer therapies might be particularly beneficial for HIV-positive people.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.